CHMP Recommends Wainzua For EU Approval For Hereditary Amyloidosis
AstraZeneca's Wainzua (eplontersen) has been recommended for approval in the EU by CHMP for treating adult patients with hereditary transthyretin-mediated amyloidosis polyneuropathy.
AstraZeneca's Wainzua (eplontersen) has been recommended for approval in the EU by CHMP for treating adult patients with hereditary transthyretin-mediated amyloidosis polyneuropathy.
NEAR ecosystem updates: Hackathon prize pool exceeds $1m with extended deadline due to high demand.
Experian is promoting financial freedom for Hispanics by relieving $10 million in debt, partnering with NBCUniversal Telemundo and Prince Royce at the 2024…
Ontex Group NV received a notification of significant shareholdings on October 16, 2024. Black Creek Investment Management Inc. disclosed holding 2,442,764 Ontex voting…
Novartis receives positive CHMP opinion for Kisqali® for adjuvant treatment of HR+/HER2- early breast cancer.
Thu Oct 17 21:01:33 -2024 UTC — Eksmo, a leading Russian publishing house, will present its latest literary offerings at the 76th Frankfurt…
Merck & Co., Inc. released news about their Clesrovimab (MK-1654) monoclonal antibody reducing RSV disease and hospitalizations in infants.
JPMorganChase elects Brad D. Smith to its board, effective January 21, 2025. Smith, President of Marshall University and former Intuit CEO, brings innovation…
CD PROJEKT S.A. received a request from shareholder Marcin Iwiński to convene an Extraordinary General Meeting.
Netflix Executive Bela Bajaria has been elected to the Board of Directors of The Coca-Cola Company.